Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: Analysis from the monitornet databas

Clinical and Experimental Rheumatology

Volumn 31, Issue 6, 2013, Pages 857-863

  Scirè, Carlo A ^a,b   Caporali, Roberto ^a,b   Sarzi Puttini, Piercarlo ^c   Frediani, Bruno ^d   Di Franco, Manuela ^e   Tincani, Angela ^f   Sinigaglia, Luigi ^g   Sfriso, Paolo ^h   Tirri, Rosella ⁱ   Bellis, Emanuela ^j   Delsante, Giovanni ^k   Porru, Giovanni ^l   Salafi, Fausto ^m   Giuggioli, Dilia ⁿ   Rossini, Maurizio ^o   Todoerti, Monica ^b   Bazzichi, Laura ^p   Govoni, Marcello ^q   Gerli, Roberto ^r   Raschetti, Roberto ^s   Minisola, Giovanni ^t   Montecucco, Carlomaurizio ^b   Todesco, Silvano ^h   more..

^a Epidemiology Unit   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j MAURIZIANO HOSPITAL   (Italy)

^k Polyspecialistic Medicine Internal Medicine and Rheumatology Service   (Italy)

^l DEPARTMENT OF RADIOLOGY   (Italy)

^m UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁿ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^o UNIVERSITY OF VERONA   (Italy)

^p UNIVERSITY OF PISA   (Italy)

^q UNIVERSITY OF FERRARA   (Italy)

^r UNIVERSITY OF PERUGIA   (Italy)

^s ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^t SAN CAMILLO FORLANINI HOSPITAL   (Italy)

more..

Author keywords

Anti rheumatic agents; Pharmacoepidemiology; Rheumatoid arthritis; Spondylarthropathies

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CYTOPENIA; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG EFFICACY; DRUG SURVIVAL; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; LONG TERM CARE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHARMACOEPIDEMIOLOGY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SKIN DISEASE; SPONDYLARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SPONDYLARTHRITIS; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892460666     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Singh JA, Christensen R, Wells Ga, et al, Biologics for rheumatoid arthritis an overview of Cochrane reviews.Cochrane Database Syst Rev 2009, CD007848.
2. Zink A, Listing J, Kary S, et al, Treatment continuation in patients receiving biological agents or conventional DMARD therapy, Ann Rheum Dis 2005, 64 1274-9
3. Carmona L, Gomez-Reino JJ, Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis, Data from the Spanish registry BIOBADASER.Arthritis Res Ther 2006, 8 R72.
4. Hyrich KL, Watson KD, Silman AJ, Symmons DP, Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis results from the British Society for Rheumatology Biologics Register, Rheumatology (Oxford) 2006, 45 1558-65
5. Zink A, Strangfeld A, Schneider M, et al, Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an obser-vational cohort study comparison of patients according to their eligibility for major rand-omized clinical trials, Arthritis Rheum 2006, 54 3399-407
6. Sarzi-puttini P, Antivalle M, Marche-Soni A, et al, Eficacyandsafetyofanti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN).Reumatismo 2008, 60 290-5.
7. Atzeni F, Antivalle M, Pallavicini FB, et al, Predicting response to anti-TNF treat-ment in rheumatoid arthritis patients, Autoim-mun Rev 2009, 8 431-7
8. Marchesoni A, Zaccara E, Gorla R, et al, TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients ob-served under conditions of standard clinical practice, Ann N Y Acad Sci 2009, 1173 837-46
9. Favalli EG, Desiati F, Atzeni F, et al,Serious infections during anti-TNF-alpha treatment in rheumatoid arthritis patients, Autoimmun Rev 2009, 8 266-73
10. Filippini M, Bazzani C, Favalli EG, et al, Eficacyandsafetyofanti-tumournecrosis factor in elderly patients with rheumatoid arthritis an observational study.ClinRev Allergy Immunol 2010, 38 90-6.
11. Hetland ML, Christensen IJ, Tarp U, et al, Direct comparison of treatment re-sponses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, orinliximab results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry, Arthritis Rheum 2010, 62 22-32
12. Markenson JA, Gibofsky A, Palmer WR, et al, Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis observations from the RADIUS registry, J Rheumatol 2011, 38 1273-81
13. Iannone F, Gremese E, Atzeni F, et al, Longterm retention of tumor necrosis fac-tor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry an appraisal of pre-dictors, J Rheumatol 2012, 39 1179-84
14. Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA, Survival of TNF-alpha antagonists in rheumatoid arthri-tis a long-term study, Clin Exp Rheumatol 2012, 30 31-8
15. Heiberg MS, Kaufmann C, Rodevand E, et al, The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis 6 month results from a longitudinal, observational, multicentre study, Ann Rheum Dis 2007, 66 1038-42
16. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis observational study from the British Society of Rheumatology Biologics Register, Arthri-tis Res Ther 2009, 11 R52
17. Glintborg B, Ostergaard M, Dreyer L, et al, Treatment response, drug survival, and predictors thereof in 764 patients with psori-atic arthritis treated with anti-tumor necrosis factor alpha therapy results from the nation-wide Danish DANBIO registry.Arthritis Rheum 2011, 63 382-90.
18. Wolfe F, The epidemiology of drug treat-ment failure in rheumatoid arthritis.Bail-lieres Clin Rheumatol 1995, 9 619-32.
19. Curtis JR, Jain A, Askling J, et al, A com-parison of patient characteristics and out-comes in selected European and U.S, rheu-matoid arthritis registries.Semin Arthritis Rheum 2010, 40 2-14.
20. Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S, MonitorNet the Italian multi-centre observational study aimed at estimating the risk/beneit proile of biologic agents in real-world rheumatology practice, Reumatismo 2009, 61 132-9
21. Prevoo ML, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LB, Van Riel PL, Modiieddiseaseactivityscoresthat include twenty-eight-joint counts, Develop-ment and validation in a prospective longi-tudinal study of patients with rheumatoid arthritis, Arthritis Rheum 1995, 38 44-8
22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A A, newapproachtodeiningdiseasestatusin ankylosing spondylitis the Bath Ankylosing Spondylitis Disease Activity Index, J Rheu-matol 1994, 21 2286-91
23. Ranza R, Marchesoni A, Calori G, et al, The Italian version of the Functional Disabil-ity Index of the Health Assessment Question-naire, A reliable instrument for multicenter studies on rheumatoid arthritis.Clin Exp Rheumatol 1993, 11 123-8.
24. Calin A, Garrett S, Whitelock H, et al, A new approach to deining functional ability in ankylosing spondylitis the development of the Bath Ankylosing Spondylitis Func-tional Index, J Rheumatol 1994, 21 2281-5
25. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, Impact of concomitant use of DMARDs on the per-sistence with anti-TNF therapies in patients with rheumatoid arthritis results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis 2011, 70 583-9
26. Scirè CA, Verstappen SM, Mirjafari H, et al, Reduction of long-term disability in in-lammatory polyarthritis by early and persis-tent suppression of joint inlammation results from the Norfolk Arthritis Register, Arthritis Care Res (Hoboken) 2011, 63 945-52
27. Heiberg MS, Koldingsnes W, Mikkels-En K, et al, The comparative one-year per-formance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondyli-tis results from a longitudinal, observation-al, multicenter study, Arthritis Rheum 2008, 59 234-40
28. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML, Predictors of treatment response and drug continuation in 842 patients with anky-losing spondylitis treated with anti-tumour necrosis factor results from 8 years' surveil-lance in the Danish nationwide DANBIO registry, Ann Rheum Dis 2010, 69 2002-8
29. Punzi L, Matucci CM, Cantini F, et al, Treatment patterns of anti-TNF agents in Italy an observational study.Reumatismo 2011, 63 18-28.
30. Du Pan SM, Scherer A, Gabay C, Finckh A, Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients.Ann Rheum Dis 2012, 71 997-9.
31. Salvarani C, Pipitone N, Marchesoni A, et al, Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis update from the Italian Society for Rheumatology, Clin Exp Rheumatol 2011, 29 (Suppl 66) S28-S41
32. Favalli EG, Caporali R, Sinigaglia L, et al, Recommendations for the use of bio-logic therapy in rheumatoid arthritis update from the Italian Society for Rheumatology II, Safety, Clin Exp Rheumatol 2011, 29 (Suppl 66) S15-S27
33. Caporali R, Conti F, Alivernini S, et al, Recommendations for the use of biologic therapy in rheumatoid arthritis update from the Italian Society for Rheumatology I, Ef-icacy, Clin Exp Rheumatol 2011, 29 (Suppl 66) S7-14
34. Van Schouwenburg PA, Rispens T, Wolbink GJ, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nat Rev Rheumatol 2013, 9 164-72